Comparison of Efficacy of Ivabradine With Traditional Therapy in Patients With Left Ventricular Dysfunction
Umair Ali1, Tanveer Ahmad2, Jehanzeb Khan3,4
1Cardiology, Khyber Teaching Hospital Peshawar Pakistan, Peshawar, PAK.
Insights
Ivabradine significantly improved heart failure symptoms, enhancing New York Heart Association (NYHA) classifications compared to traditional therapy alone. This heart rate-lowering drug offers a promising addition for managing congestive heart failure patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure exacerbations increase hospitalizations and mortality, with elevated heart rate as a key concern.
- Conventional treatments are being augmented with heart rate-controlling medications.
Purpose of the Study:
- To compare the efficacy of ivabradine versus traditional treatment in patients with left ventricular systolic dysfunction.
Main Methods:
- A randomized controlled trial involving 238 heart failure patients (aged 30-65) was conducted.
- Patients were assigned to traditional therapy or traditional therapy plus ivabradine.
- Outcomes were evaluated based on New York Heart Association (NYHA) classifications after two months.
Main Results:
- Both groups had similar baseline NYHA classifications (NYHA 3 and 4).
- Ivabradine add-on therapy showed significantly greater improvements in NYHA classifications (NYHA 2, 3, and 4) compared to traditional treatment alone (p < 0.05).
Conclusions:
- Optimizing heart rate with ivabradine in heart failure patients leads to improved NYHA functional classifications.
- Ivabradine represents a valuable therapeutic option for managing congestive heart failure.
Background:
Heart failure patients usually present with disease exacerbation that overburdens the hospitals and also increases the risk of mortality with increased heart rate being the main issue. Consideration is being given to drugs for sole heart rate control in addition to conventional therapy.
Objective:
To compare the outcomes of ivabradine to traditional treatment in patients with left ventricular systolic dysfunction.
Methodology:
This randomized controlled trial was conducted in the Department of Cardiology, Khyber Teaching Hospital, Peshawar from November 1, 2020, to May 31, 2021. Patients aged 30-65 years of age and of either gender with heart failure were enrolled in the study. Patients were screened for New York Heart Association (NYHA) class and were enrolled into one of the two groups. In group 1, patients were started on traditional treatment, while group 2 patients were given ivabradine as an add-on therapy. Follow-up was made at the end of the second month for evaluation of the outcomes.
Results:
Each group had 119 patients, with a mean age of 58.05±4.98 years. Group 1, consisted of 61.3% of the patients in NYHA 3, while 38.65% were in NYHA 4. In group 2, NYHA 3 and NYHA 4 patients were 59.6% and 40.3%, respectively. Upon follow-up, there were greater improvements in group 2 as compared to group 1 based on NYHA classifications, with NYHA 2 [47.05% (group 2) vs. 13.44% (group 1)], NYHA 3 [42.85% (group 2) vs. 61.34% (group 1)] and NYHA 4 [10.08% (group 2) vs. 25.21% (group 1)], p < 0.05.
Conclusions:
Obtaining a more optimal heart rate with ivabradine in patients with congestive heart failure is reflected in an improvement in NYHA classification.
More Related Videos
10:17Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
Published on: April 11, 2025
06:57Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
Published on: January 31, 2019
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
01:29Cardiomyopathy V: Interprofessional Care
01:30Heart Failure V: Medical Management
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: β-Blockers
01:26Heart Failure Drugs: Inotropic Agents